An Open-Label Single-Dose Crossover Pharmacokinetic Study to Compare CTP-543 to Jakafi® in Healthy Volunteers
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Deuruxolitinib (Primary) ; Ruxolitinib
- Indications Alopecia areata
- Focus Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 27 Mar 2017 Status changed from recruiting to completed.
- 15 Nov 2016 New trial record